Sodium Oligomannate for Health & Longevity - Quick Reference Sheet

Sodium Oligomannate for Health & Longevity

Created on 09/25/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Grok 4 – Audit

Sodium oligomannate is an oral sugar-chain drug from brown seaweed for mild to moderate Alzheimer's disease. One company-run trial found a better memory-and-thinking score without a clear gain in daily independence, behavior, or clinician's rating; an earlier trial missed its main thinking result. Harm looked limited; high blood lipids were more common. No human test exists without dementia. China's approval was not renewed in 2025 and production was reported stopped. (Full Review)

Protocol

Studied dose
450 mg orally twice daily
900 mg/day; three 150 mg capsules each time; phase 3 regimen and former Chinese labeled dose
Time of day
Morning and evening
About 12 hours apart; half-life about 11 hours; trials did not require a fast
No second schedule
No published longevity-clinic dose
This schedule in mild-to-moderate Alzheimer's disease, not in healthy adults
Time to effect
Cognitive-score gap
Week 4
Present in the phase 3 trial
Cognitive-score gap
Week 36
Still present at the end of that trial
Daily function
No separation
Did not separate over that span

Benefits

Contraindications
  • Known hypersensitivity to sodium oligomannate or the capsule contents (absolute contraindication)
  • Inadequate liver function (no published Child-Pugh cutoff; caution)
  • Resting heart rate under 50 beats per minute (caution)
Key Interactions
  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine (severity unknown)
  • Broad-spectrum antibiotics (ciprofloxacin, amoxicillin-clavulanate; caution)
  • Statins (atorvastatin, rosuvastatin; monitor)
  • Over-the-counter pain drugs (ibuprofen, naproxen; severity none identified)
  • Gut or lipid supplements (probiotics, red yeast rice; caution)

Risk & Side Effects

  • High:
  • Medium: Higher blood lipids
  • Nasopharyngitis
  • Dry mouth
  • Blood in the urine
  • Liver laboratory readings
  • Low:
  • Speculative:

Monitoring

Marker Target Why
Fasting LDL-C and triglycerides LDL-C under 100 mg/dL (under 70 mg/dL if artery disease is present); triglycerides under 100 mg/dL High blood lipids were more common on drug than on placebo
eGFR Over 90 mL/min/1.73 m², or stable versus the person's own baseline if no oligomannate-specific target is set The absorbed fraction is cleared by the kidney in animal studies
ALT Under 25 U/L, or stable versus baseline where no drug-specific target exists The approval safety summary listed higher readings on drug than on placebo
Cognitive score (MMSE or ADAS-Cog) No fixed blood-style optimum; change from the person's baseline on the same test is followed This is the outcome that moved in the phase 3 trial

Cadence: Before a first dose: cognitive score, fasting lipids, kidney filtration, and liver enzymes. Cognitive score and lipids again at about 4 weeks, then every 3–6 months; kidney and liver tests on that same cadence unless a result is abnormal.

Qualitative Assessment

  • Recent-memory slips during ordinary tasks
  • Handling of medications, money, or appointments
  • Mood and irritability across the week
  • New nose-and-throat irritation or a sustained change in stamina
  • New blood in the urine